Search

Your search keyword '"Armstrong, Paul W."' showing total 81 results

Search Constraints

Start Over You searched for: Author "Armstrong, Paul W." Remove constraint Author: "Armstrong, Paul W." Journal journal of the american college of cardiology (jacc) Remove constraint Journal: journal of the american college of cardiology (jacc)
81 results on '"Armstrong, Paul W."'

Search Results

1. Transatlantic Comparison of ST-Segment Elevation Myocardial Infarction Guidelines: Insights From the United States and Europe.

2. Navigating Choices Among a Sea of Comorbidities.

5. Baseline Q-Wave Surpasses Time From Symptom Onset as a Prognostic Marker in ST-Segment Elevation Myocardial Infarction Patients Treated With Primary Percutaneous Coronary Intervention

6. Effects of Selective Matrix Metalloproteinase Inhibitor (PG-116800) to Prevent Ventricular Remodeling After Myocardial Infarction: Results of the PREMIER (Prevention of Myocardial Infarction Early Remodeling) Trial

10. THE RELATIONSHIP BETWEEN BODY WEIGHT CHANGE DURING HOSPITALIZATION FOR ACUTE HEART FAILURE AND PATIENT CHARACTERISTICS, MARKERS OF CONGESTION, AND OUTCOMES: FINDINGS FROM ASCEND-HF.

12. Biomarker-Based Risk Model to Predict Cardiovascular Mortality in Patients With Stable Coronary Disease.

13. 833-5 Markers of inflammation predict mortality and are reduced by pexelizumab in patients with acute myocardial infarction: Insights from the complement inhibition in myocardial infarction treated with angioplasty (COMMA) trial.

14. 810-4 Pexelizumab, a C5 complement inhibitor, reduces 30-day mortality in patients undergoing coronary artery bypass surgery or receiving reperfusion therapy for acute myocardial infarction.

17. Post-Discharge Bleeding and Mortality Following Acute Coronary Syndromes With or Without PCI.

18. Physical Activity and Mortality in Patients With Stable Coronary Heart Disease.

19. Hospitalization for Recently Diagnosed Versus Worsening Chronic Heart Failure: From the ASCEND-HF Trial.

21. Reply

22. Validation of BARC Bleeding Criteria in Patients With Acute Coronary Syndromes: The TRACER Trial.

23. Spontaneous MI After Non-ST-Segment Elevation Acute Coronary Syndrome Managed Without Revascularization: The TRILOGY ACS Trial.

24. Impact of CYP2C19 Metabolizer Status on Patients With ACS Treated With Prasugrel Versus Clopidogrel.

25. Cardiovascular Drug Development: Is it Dead or Just Hibernating?

26. Vorapaxar in Acute Coronary Syndrome Patients Undergoing Coronary Artery Bypass Graft Surgery: Subgroup Analysis From the TRACER Trial (Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome)

27. Vorapaxar in Acute Coronary Syndrome Patients Undergoing Coronary Artery Bypass Graft Surgery: Subgroup Analysis From the TRACER Trial (Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome).

28. Cardiac troponin after percutaneous coronary intervention and 1-year mortality in non-ST-segment elevation acute coronary syndrome using systematic evaluation of biomarker trends.

29. Cardiac Troponin After Percutaneous Coronary Intervention and 1-Year Mortality in Non–ST-Segment Elevation Acute Coronary Syndrome Using Systematic Evaluation of Biomarker Trends.

30. Comparison of the Prognosis of Spontaneous and Percutaneous Coronary Intervention–Related Myocardial Infarction

31. Assessment of Dyspnea in Acute Decompensated Heart Failure: Insights from ASCEND-HF (Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure) on the Contributions of Peak Expiratory Flow

32. Association of Mortality With Years of Education in Patients With ST-Segment Elevation Myocardial Infarction Treated With Fibrinolysis

33. Declining In-Hospital Mortality and Increasing Heart Failure Incidence in Elderly Patients With First Myocardial Infarction

34. 1118-102 Baseline white blood cell count and interleukin-6 levels provide complementary prognostic information in acute myocardial infarction: Results from the CARDINAL trial.

35. Short- and Long-Term Risk Stratification in Acute Coronary Syndromes: The Added Value of Quantitative ST-Segment Depression and Multiple Biomarkers

36. A Comparison of the Clinical Impact of Bleeding Measured by Two Different Classifications Among Patients With Acute Coronary Syndromes

37. Patients With Prolonged Ischemic Chest Pain and Presumed-New Left Bundle Branch Block Have Heterogeneous Outcomes Depending on the Presence of ST-Segment Changes

38. Aborted myocardial infarction in patients with ST-segment elevation: Insights from the assessment of the safety and efficacy of a new thrombolytic regimen-3 trial electrocardiographic substudy

39. Outcome of acute ST-segment elevation myocardial infarction in diabetics treated with fibrinolytic or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: Lessons from the GUSTO V trial

40. From controlled trials to clinical practice: monitoring transmyocardial revascularization use and outcomes

41. Outcome of urgent and elective percutaneous coronary interventions after pharmacologic reperfusion with tenecteplase combined with unfractionated heparin, enoxaparin, or abciximab.

42. Outcome of urgent and elective percutaneous coronary interventions after pharmacologic reperfusion with tenecteplase combined with unfractionated heparin, enoxaparin, or abciximab

43. Troponin T and quantitative ST-segment depression offer complementary prognostic information in the risk stratification of acute coronary syndrome patients

44. Prognostic significance of elevated troponin i after percutaneous coronary intervention

45. The prognostic value of creatine kinase elevations extends across the whole spectrum of acute coronary syndromes

48. INTERLEUKIN-6 IS ASSOCIATED WITH, BUT DOES NOT INDEPENDENTLY PREDICT, MORTALITY IN ACUTE HEART FAILURE: AN ASCEND-HF SUBSTUDY.

Catalog

Books, media, physical & digital resources